Calcitonin Gene-Related Peptide (CGRP) inhibits microglia inflammatory activation in vitro. We here analyzed the involvement of CGRP and Receptor Component Protein (RCP) in experimental autoimmune encephalomyelitis (EAE). Alpha-CGRP deficiency increased EAE scores which followed the scale alpha-CGRP null N heterozygote N wild type. In wild type mice, CGRP delivery into the cerebrospinal fluid (CSF) 1) reduced chronic EAE (C-EAE) signs, 2) inhibited microglia activation (revealed by quantitative shape analysis), and 3) did not alter GFAP expression, cell density, lymphocyte infiltration, and peripheral lymphocyte production of IFN-gamma, TNF-alpha, IL-17, IL-2, and IL-4. RCP (probe for receptor involvement) was expressed in white matter microglia, astrocytes, oligodendrocytes, and vascular-endothelial cells: in EAE, also in infiltrating lymphocytes. In relapsing-remitting EAE (R-EAE) RCP increased during relapse, without correlation with lymphocyte density. RCP nuclear localization (stimulated by CGRP in vitro) was I) increased in microglia and decreased in astrocytes (R-EAE), and II) increased in microglia by CGRP CSF delivery (C-EAE). Calcitonin like receptor was rarely localized in nuclei of control and relapse mice. CGRP increased in motoneurons. In conclusion, CGRP can inhibit microglia activation in vivo in EAE. CGRP and its receptor may represent novel protective factors in EAE, apparently acting through the differential cell-specific intracellular translocation of RCP.
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Introduction
Calcitonin Gene-Related Peptide (CGRP), a peptide generated from tissue-specific alternative splicing of the calcitonin gene (Amara et al., 1982) , and adrenomedullin (Kitamura et al., 1993) are two homologous neuropeptides that signal through a common core G-protein-coupled receptor named Calcitonin-Like Receptor (CLR, Chang et al., 2004) . However, CLR is an unusual G-protein-coupled receptor since it requires accessory proteins for its function. Three single-transmembrane accessory proteins have been identified and named Receptor Activity Modifying Proteins (RAMPs) 1-3. CLR is a high-affinity receptor for CGRP when co-expressed with RAMP1, and for adrenomedullin when co-expressed with RAMP2 or RAMP3 (McLatchie et al., 1998) . These receptor complexes interact with an additional cytoplasmic protein, the CGRP-Receptor Component Protein (RCP), which is the functional link with the intracellular signaling pathways and, in particular, with cAMP formation (Evans et al., 2000; Egea and Dickerson, 2012) .
CGRP and adrenomedullin can modulate both neural and immune systems. CGRP is expressed mainly by neuronal cells and promotes astrocytic and neuronal differentiation (D'Antoni et al., 2010) and modulates the activity of glial cells (Uezono et al., 2001; Wang et al., 2009) . CGRP not only promotes neurogenic inflammation in the periphery (Holzer, 1998) and brain (during headache; Durham, 2006) , but also protects against inflammatory injuries, as in LPS-induced local acute Journal of Neuroimmunology 271 (2014) 18-29 
